Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Open-Label Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

NCT03773133 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT03773133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03773133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Open-Label Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
Lead sponsor
Ipsen
Phase
Phase 1/2
Overall status
Terminated
Start date
May 14, 2019
Completion date
October 10, 2019
Enrollment
9 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer and breast cancer